Podcasts
UCB go ‘Under the Skin’ with new hidradenitis suppurativa (HS) podcast
As part of UCB’s commitment to raising the standard of care for patients suffering from hidradenitis suppurativa (HS), ‘Under the Skin’, UCB’s latest podcast series, draws back the curtain on this debilitating, chronic inflammatory skin disease.
Aimed at healthcare professionals looking to learn more about HS, this podcast aims to shed light on this under-recognised disease, following the often complex patient journey from pre-diagnosis through to disease management.
Hosted by Dr Barry McGrath (HS patient advocate and co-founder of HS Ireland), each episode in this five-part series invites a new expert guest to share their knowledge of treating HS and to discuss one of the many facets of the patient experience.
All currently available episodes are listed below, and you can subscribe to the series on Spotify to catch all episodes as they’re released (for healthcare professionals only).
What is the bigger picture in HS?
Episode 1 welcomes Dr John Ingram (Consultant Dermatologist at Cardiff University) in conversation with our host Dr Barry McGrath (co-founder of HS Ireland) to share an overview of HS, its presentation in patients, epidemiology and global prevalence.
Episode chapters:
[01:25] Introducing Dr John Ingram
[02:44] Background and pathobiology of HS
[09:00] HS patient demographics
[15:18] HS global and EU epidemiology
[25:58] HS among other diseases
Speaker disclosures
Dr Barry McGrath and Dr John Ingram have received consulting fees, research or institutional support and educational grants from UCB.
Barry McGrath, PhD, has received consultancy/advisory board disease related honoraria from Novartis and UCB.
Dr John Ingram receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, and UCB, and has served on advisory boards for Insmed, Kymera Therapeutics, and Viela Bio. He is a co-copyright holder of HiSQOL, Investigator Global Assessment, and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments.
Dr Barry McGrath and Professor Falk Bechara have received consulting fees, research or institutional support and educational grants from UCB.
Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB.
Falk G. Bechara has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma GmbH, UCB Pharma, Incyte Corporation, Janssen-Cilag GmbH, MoonLake, Dr. Wolff, Mölnlycke and Celltrion.
How does HS affect patients?
For our second episode, our host Dr Barry McGrath is joined by Professor Falk Bechara, a dermatologist who is Head of the Department of Dermatologic Surgery at the Ruhr University Bochum in Germany. Together, they discuss the profound physical, psychological and social impacts that hidradenitis suppurativa can have on a patient’s quality of life.
Please note, this episode briefly discusses suicide (20:28–22:35); listener discretion is advised.
Episode chapters:
[00:30] Introducing Professor Falk Bechara
[01:45] Background of HS
[03:03] Impact on patient’s quality of life
[12:08] Physical symptoms of HS
[18:36] Symptoms of HS on a person’s mental and psychological health
[25:48] HS effects on a person’s social life
[31:27] Measurement of HS severity
[36:43] Episode close
Stay up to date with the latest UCB news on our social media channel: LinkedIn.
Speaker disclosures
Dr Barry McGrath and Professor Falk Bechara have received consulting fees, research or institutional support and educational grants from UCB.
Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB.
Falk G. Bechara has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma GmbH, UCB Pharma, Incyte Corporation, Janssen-Cilag GmbH, MoonLake, Dr. Wolff, Mölnlycke and Celltrion.